Single-center phase 2 trial | Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas.
11 Aug, 2022 | 11:52h | UTCDurvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK pic.twitter.com/BP7fz9FWRw
— The Lancet Oncology (@TheLancetOncol) August 5, 2022